Bellicum Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Bellicum Pharmaceuticals (NASDAQ:BLCM) announced equity inducement grants of 135,000 stock options to two new employees, effective June 30, 2022. The options have an exercise price of $1.18 per share, vesting over four years. 25% will vest on the one-year anniversary, with the remainder vesting monthly thereafter. This grant adheres to Nasdaq Listing Rule 5635(c)(4) and is part of the company's equity incentive plan. Bellicum focuses on controllable cellular immunotherapies for cancer, aiming to produce more effective CAR-T therapies.
- Inducement grants of 135,000 stock options may attract talented employees.
- Stock options priced at $1.18 could provide long-term incentives linked to company performance.
- None.
HOUSTON, July 01, 2022 (GLOBE NEWSWIRE) -- Bellicum Pharmaceuticals, Inc. (NASDAQ:BLCM), a leader in developing novel, controllable cellular immunotherapies for cancers, today announced equity inducement grants to 2 new employees consisting of an aggregate of 135,000 stock options. The Compensation Committee of the Board of Directors approved the grants with an effective date of June 30, 2022. The stock options were granted as inducements material to the employees entering into employment with the Company in accordance with Nasdaq Listing Rule 5635(c)(4).
The stock options have an exercise price of
About Bellicum Pharmaceuticals
Bellicum is a clinical stage biopharmaceutical company striving to deliver cures through controllable cell therapies. The company’s next-generation product candidates are differentiated by powerful cell signaling technologies designed to produce more effective CAR-T cell therapies. Bellicum’s GoCAR-T® product candidates, BPX-601 and BPX-603, are designed to be more efficacious CAR-T cell products capable of overriding key immune inhibitory mechanisms. More information about Bellicum can be found at www.bellicum.com or follow us on Twitter or LinkedIn.
Source: Bellicum Pharmaceuticals
Investors:
Robert H. Uhl
Managing Director
Westwicke IR
858-356-5932
Robert.uhl@westwicke.com
FAQ
What is the recent stock option grant by Bellicum Pharmaceuticals?
What is the exercise price for the new stock options granted by Bellicum?